Loading...
•
Sep 30
•/
BioNTech SE Q3 2025 Earnings Report
BioNTech SE reported a net loss in Q3 2025 despite higher revenues, impacted by elevated R&D spending and other operating expenses.
Key Takeaways
BioNTech posted €1.52 billion in revenue for Q3 2025, driven by partnership-related income, but reported a net loss of €28.7 million as R&D and other operating costs rose.
Revenue increased to €1.52 billion, primarily from BMS collaboration payments.
Reported a net loss of €28.7 million versus a profit in Q3 2024.
R&D and SG&A expenses remained high due to oncology program investments.
Cash, cash equivalents, and security investments totaled €16.7 billion.
BioNTech SE
BioNTech SE
Forward Guidance
BioNTech raised its full-year revenue outlook and reduced expected R&D, SG&A, and capital expenditures, signaling cost discipline amid ongoing oncology investments.
Positive Outlook
- Raised full-year revenue guidance to €2.6–2.8 billion.
- Lowered R&D expense guidance to €2.0–2.2 billion.
- Lowered SG&A expense guidance to €550–650 million.
- Capital expenditures guidance reduced to €200–250 million.
- Received $1.5 billion from BMS collaboration.
Challenges Ahead
- Company still expects a net loss for FY 2025.
- COVID-19 vaccine revenues may be affected by public policy changes.
- Inventory write-downs expected to impact gross profit from Pfizer territory.
- R&D costs remain significant despite reduction in guidance.
- Ongoing legal and regulatory risks could affect future performance.